Skip to main content

CLINICAL TRIAL article

Front. Genet.
Sec. Genetics of Common and Rare Diseases
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1523304

Genetic variation in patent foramen ovale: a case-control genome-wide association study

Provisionally accepted
Bosi Dong Bosi Dong Yajiao Li Yajiao Li *Fandi Ai Fandi Ai *Jia Geng Jia Geng *Ting Tang Ting Tang *Wan Peng Wan Peng Yusha Tang Yusha Tang *Hui Wang Hui Wang *Zixuan Tian Zixuan Tian *Fengxiao Bu Fengxiao Bu *Lei Chen Lei Chen *
  • West China Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

    Background: Patent foramen ovale (PFO) is a congenital defect between the atria, resulting in abnormal hemodynamics. We conducted a genome-wide association study (GWAS) to identify common genetic variants associated with PFO.Methods: We performed a whole genome sequencing in a discovery cohort of 3,227 unrelated Chinese participants screened for PFO via contrast transthoracic echocardiography (cTTE). Singlenucleotide polymorphisms (SNPs) associated with PFO were further validated by Sanger sequencing and subsequently were evaluated in a validation cohort. Expression quantitative trait loci (eQTL) analysis was conducted using the GTEx database. Single-cell sequencing analyses with pseudotime trajectory modeling were employed to evaluate their expression in human fetal hearts.Results: The case-control GWAS of discovery cohort ultimately included 517 cases and 517 demographically matched controls. Of the 7,040,407 variants assessed, we identified rs1227675732 (OR = 2.903; 95% CI, 1.961 to 4.297; p = 3.05 × 10 -8 ), rs62206790 (OR = 2.780; 95% CI, 1.864 to 4.146; p = 2.02 × 10 -7 ), rs879176184 (OR = 2.724; 95% CI, 1.822 to 4.073; p = 4.30 × 10 -7 ) and rs13115019 (OR = 2.437; 95% CI, 1.702 to 3.488; p = 5.80 × 10 -7 ) as high-risk variants for PFO, while rs57922961 (OR = 0.5081; 95% CI, 0.388 to 0.666; p = 6.82 × 10 -7 ) was identified as protective variant. These variations were replicated in the validation cohort (111 cases and 152 controls). Single-cell sequencing showed that CNOT2, KCNMB4, MLLT10, IGBP1, and FRG1 were highly expressed with significant changes during heart development.Conclusions: The identification of susceptible loci for PFO might provide insights into the pathogenesis of PFO and contribute to understanding heart development.

    Keywords: patent foramen ovale, Genome-Wide Association Study, heart development, common variants, single-cell sequancing

    Received: 05 Nov 2024; Accepted: 24 Dec 2024.

    Copyright: © 2024 Dong, Li, Ai, Geng, Tang, Peng, Tang, Wang, Tian, Bu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yajiao Li, West China Hospital, Sichuan University, Chengdu, China
    Fandi Ai, West China Hospital, Sichuan University, Chengdu, China
    Jia Geng, West China Hospital, Sichuan University, Chengdu, China
    Ting Tang, West China Hospital, Sichuan University, Chengdu, China
    Yusha Tang, West China Hospital, Sichuan University, Chengdu, China
    Hui Wang, West China Hospital, Sichuan University, Chengdu, China
    Zixuan Tian, West China Hospital, Sichuan University, Chengdu, China
    Fengxiao Bu, West China Hospital, Sichuan University, Chengdu, China
    Lei Chen, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.